<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02612623</url>
  </required_header>
  <id_info>
    <org_study_id>7264-021</org_study_id>
    <secondary_id>AF219-021</secondary_id>
    <nct_id>NCT02612623</nct_id>
  </id_info>
  <brief_title>An 8-Week Refractory Chronic Cough Study</brief_title>
  <official_title>A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afferent Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afferent Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant
      (AF-219) in subjects with refractory chronic cough.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2015</start_date>
  <completion_date type="Actual">May 18, 2016</completion_date>
  <primary_completion_date type="Actual">May 4, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Cough Frequency</measure>
    <time_frame>8 weeks</time_frame>
    <description>objective cough monitoring - 24 hour sound recording</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Refractory Chronic Cough</condition>
  <arm_group>
    <arm_group_label>Gefapixant 15 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefapixant 30 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefapixant 50 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 50 mg gefapixant tablet administered by mouth twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to match gefapixant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matching placebo tablets administered by mouth twice daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefapixant</intervention_name>
    <arm_group_label>Gefapixant 15 mg twice daily</arm_group_label>
    <arm_group_label>Gefapixant 30 mg twice daily</arm_group_label>
    <arm_group_label>Gefapixant 50 mg twice daily</arm_group_label>
    <other_name>AF-219</other_name>
    <other_name>MK-7264</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for gefapixant)</intervention_name>
    <arm_group_label>Placebo to match gefapixant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and Men between 18 and 80 years of age inclusive

          -  Have refractory chronic cough

          -  Women of child-bearing potential must use 2 forms of acceptable birth control

          -  Have provided written informed consent.

          -  Are willing and able to comply with all aspects of the protocol.

        Exclusion Criteria:

          -  Current smoker

          -  FEV1/FVC &lt; 60%

          -  History of upper respiratory tract infection or recent significant change in pulmonary
             status within 4 weeks of the Baseline

          -  History of opioid use within 1 week of the Baseline Visit

          -  Body mass index (BMI) &lt;18 kg/m2 or â‰¥ 37 kg/m2

          -  History of concurrent malignancy or recurrence of malignancy within 2 years prior to
             Screening (not including subjects with &lt;3 excised basal cell carcinomas)

          -  Screening systolic blood pressure (SBP) &gt;160 mm Hg or a diastolic blood pressure (DBP)
             &gt;90 mm Hg

          -  Significantly abnormal laboratory tests at Screening

          -  Clinically significant abnormal electrocardiogram (ECG)

          -  Pregnant or Breastfeeding

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with trial participation or
             investigational product administration or may interfere with the interpretation of
             trial results and, in the judgment of the Investigator or Sponsor, would make the
             subject inappropriate for entry into this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afferent Pharmaceuticals Clinical Research</last_name>
    <role>Study Director</role>
    <affiliation>Afferent Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afferent Investigative Site</name>
      <address>
        <city>Greenfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

